A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients With Mile-to-Moderate Huntington Disease

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients With Mile-to-Moderate Huntington Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Latrepirdine (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms HORIZON
  • Sponsors Medivation
  • Most Recent Events

    • 28 Apr 2012 Additional trial location added as reported by European Clinical Trials Database (Parent trial: EudraCT2009-011800-44).
    • 11 Apr 2011 Status changed from active, no longer recruiting to completed.
    • 11 Apr 2011 Negative topline results reported in a Pfizer and Medivation media release; the companies have discontinued development of latrepirdine in Huntington's disease based on the results of the HORIZON trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top